The DO-HEALTH trial found small epigenetic-clock signals with omega-3, vitamin D and exercise. Here is what changed, what did not, and how to decide safely.
Omega-3 and biological aging have met in a tempting headline: one gram a day, vitamin D, exercise and epigenetic clocks that move by a few months. The useful reading is less flashy and more clinically valuable. DO-HEALTH did not prove that a supplement rejuvenates people. It did show that a simple intervention can slightly shift some DNA methylation markers in healthy older adults.
That distinction matters. In longevity medicine, a 3 or 4 month difference in an epigenetic clock is not a guarantee of longer life. It is also not meaningless. It is a molecular signal that should be read alongside strength, muscle mass, infections, falls, cancer, sleep, diet, inflammation and adherence.
At Progevita, we read this study as a useful maturity test for the field: epigenetic clocks can help evaluate interventions, but they do not replace clinical outcomes. The question is not "which supplement lowers my biological age?" It is "which deficiency, habit or measurable risk can I improve without losing safety or function?"
Clinical and editorial review: July 2026. This article is educational and does not replace medical assessment. It does not recommend universal omega-3 or vitamin D supplementation, and it does not treat epigenetic clocks as standalone diagnoses.
Quick Answer: What DO-HEALTH Showed
| Question | Clinical answer |
|---|---|
| What was tested? | Vitamin D3 at 2,000 IU/day, omega-3 at 1 g/day and a simple home exercise program over 3 years. |
| In whom? | 777 Swiss DO-HEALTH participants, aged 70+, relatively healthy and active. |
| Which markers? | PhenoAge, GrimAge, GrimAge2 and DunedinPACE, four DNA methylation measures related to biological age or pace of aging. |
| What changed? | Omega-3 alone slowed signals in PhenoAge, GrimAge2 and DunedinPACE. The full omega-3, vitamin D and exercise combination showed additive benefit on PhenoAge. |
| How large was the effect? | Small: 0.16-0.32 standardized units, equivalent to about 2.9-3.8 months over 3 years. |
| What did it not prove? | It did not prove individual mortality reduction, validate supplements for everyone or turn an epigenetic clock into an isolated treatment target. |
The Study: 777 People, 3 Years and Four Clocks
The paper published in Nature Aging in 2025 was a post hoc analysis of the DO-HEALTH trial. The original trial included 2,157 European adults aged 70 years or older. The Bio-Age substudy analyzed 777 Swiss participants with blood samples at baseline and after 3 years.
The 2 x 2 x 2 factorial design compared three interventions alone and in combination: vitamin D3 at 2,000 IU per day, marine omega-3 at 1 g per day and a simple home exercise program for 30 minutes, three times per week. The paper reports that the omega-3 provided 330 mg EPA and 660 mg DHA.
The clocks do not all measure the same thing. PhenoAge and GrimAge were trained to capture biological risk and mortality better than chronological age. GrimAge2 is a later update. DunedinPACE measures pace of aging rather than an age in years. That is why the study connects naturally with our guide to biological aging speed and our primer on epigenetic clocks.
The main signal was clear but small: omega-3 reduced acceleration or pace signals in three of the four main clocks. Vitamin D and exercise did not consistently move the clocks by themselves. The full combination added benefit on PhenoAge, not on every clock.
Months, Not Decades: Why Effect Size Matters
The viral result was "up to 4 months less biological aging". Technically, the article reports 2.9 to 3.8 months, depending on the clock and model. That does not mean living 4 months longer, and it does not mean whole-body rejuvenation. It means a small molecular difference observed in blood.
Small does not mean useless. If an intervention is low risk for the right person, easy to sustain for years and shifts aging markers in the right direction, it deserves attention. It does not deserve to be sold as an anti-aging pill.
Progevita Reading
- Good news: this was a randomized trial with high adherence and modern methylation measures.
- Important caution: it was a post hoc analysis in a healthy, active Swiss subgroup, not a mirror of all older adults.
- Good practice: use the finding to personalize diet, omega-3, vitamin D and exercise, not to supplement blindly.
- Clinical standard: the clock is one layer. Function leads: strength, gait, falls, sleep, infections, metabolism and quality of life.
What Headlines Often Miss
- It was not whole-body rejuvenation: it was a small difference in blood DNA methylation markers.
- It was not universal supplementation: likely benefit depends on baseline intake, EPA/DHA status, age, risk and adherence.
- It was not vitamin D alone: vitamin D did not clearly move the main clocks by itself in DO-HEALTH Bio-Age.
- It was not a standalone clinical target: if a clock improves while strength, sleep or cardiometabolic risk worsens, the plan is failing.
The Original Trial Was Not a Dramatic Clinical Win
To understand DO-HEALTH, the 2020 JAMA paper also matters. In the full trial, vitamin D, omega-3 and the strength exercise program did not produce statistically significant benefits for the six primary endpoints at 3 years. In plain terms: a positive molecular analysis does not erase the more cautious main clinical result.
There were still interesting secondary signals. In DO-HEALTH, omega-3 was linked to fewer infections in some analyses. The three-treatment combination reduced odds of becoming prefrail among participants who were free of frailty at baseline, and an exploratory analysis found fewer invasive cancers with the full combination. These data fit the geroscience hypothesis, but they do not authorize individual promises.
In 2026, another DO-HEALTH paper added useful context: in npj Aging, participants who developed invasive cancer showed greater decline in grip strength and chair-stand performance, and already had several months of baseline epigenetic acceleration on some clocks. That supports a practical point: clocks are most useful when read next to real physical function.
How DO-HEALTH Fits With VITAL
VITAL helps keep the enthusiasm grounded. It was a much larger trial, with 25,871 US adults, testing vitamin D3 at 2,000 IU/day and marine omega-3 at 1 g/day for primary prevention of cancer and cardiovascular disease. In the main results, neither vitamin D nor omega-3 significantly reduced invasive cancer incidence or major cardiovascular events.
That does not contradict DO-HEALTH Bio-Age. It places it in context. An epigenetic clock can change before we see fewer heart attacks, cancers or deaths in a given trial. The reverse can also happen: a molecular marker may not capture every clinical benefit.
The VITAL telomere substudy, published in The American Journal of Clinical Nutrition in 2025, added another piece: vitamin D3 reduced leukocyte telomere attrition by 0.14 kb over 4 years, while omega-3 had no significant effect on telomere length. The interpretation is not "vitamin D rejuvenates". It is that different aging markers respond differently and still need clinical translation.
Limitations That Change Decisions
- Post hoc: the epigenetic analysis was not the original primary endpoint of DO-HEALTH.
- Swiss subgroup: the 777 participants were healthier and more active than many adults over 70 seen in real clinics.
- Blood, not whole body: clocks were measured in blood; we do not know whether the same change occurred in muscle, brain, bone or arteries.
- Two timepoints: baseline and year 3 increase noise compared with follow-up designs with more intermediate measures.
- No gold standard: there is no single validated marker translating "biological age" into individual survival.
- No survival proof: a clock shift does not by itself prove longer life or fewer clinical events.
Why Omega-3 May Have Stood Out
The exact mechanism is not settled. Omega-3 can influence cell membranes, inflammatory resolution, lipid metabolism, immune signaling and EPA/DHA-derived metabolites. In the DO-HEALTH analysis, omega-3 also shifted DNAm markers related to proteins such as PAI-1, leptin and TIMP-1, which connect with metabolism and inflammation.
One clinical detail matters, but it needs precision. In stratified analyses, additive PhenoAge benefits were somewhat larger in women and in people with lower baseline DHA and EPA. The separate omega-3 effect on PhenoAge was somewhat larger in people whose baseline 25-OH vitamin D was at least 20 ng/mL. These are subgroup signals, not prescribing rules.
The practical idea still matters. If someone already eats oily fish often and has a good omega-3 index, extra capsules may add less. If someone barely gets marine omega-3, the margin may be larger.
This is the difference between precision medicine and supplement marketing. The better question is not "omega-3 yes or no?" It is whether baseline status, clinical goal and risk profile make the intervention worthwhile.
Vitamin D: Correct Deficiency, Do Not Chase Megadoses
Vitamin D deserves a similar reading. In DO-HEALTH, a meaningful share of participants had 25-OH vitamin D below 20 ng/mL. Correcting deficiency can matter for bone, muscle, immune function and fall risk in selected people. But if levels are already adequate, pushing the dose higher without a goal is not a longevity strategy.
Many guidelines do not recommend routine universal screening in healthy adults. Testing does make sense with low sun exposure, frailty, osteoporosis, malabsorption, kidney disease, selected medication, obesity, bone pain, falls or suspected deficiency. In our longevity biomarkers guide, vitamin D is a contextual marker, not a trophy.
The 2024 Endocrine Society guideline even suggests against routine vitamin D supplementation above recommended intakes in healthy adults aged 50 to 74, and suggests against routine 25-OH vitamin D testing in healthy adults without an indication. In adults over 75, it favors lower daily dosing rather than high intermittent boluses when supplementation is chosen. The USPSTF, meanwhile, states that evidence is insufficient to recommend for or against screening for vitamin D deficiency in asymptomatic, nonpregnant adults.
| Data point | How we use it | Common mistake |
|---|---|---|
| 25-OH vitamin D | Detect deficiency, adjust dose, review calcium, kidney function and bone risk. | High-dose supplementation without testing or indication. |
| Omega-3 index or EPA/DHA intake | Check whether there is real room to improve omega-3 status. | Taking capsules without reviewing diet, triglycerides, medication or bleeding risk. |
| ApoB and triglycerides | Place omega-3 inside real cardiometabolic risk. | Confusing low-dose omega-3 with advanced lipid treatment. |
| Strength and gait | Confirm that the intervention improves function, not only markers. | Watching an epigenetic clock while losing muscle. |
| DunedinPACE / PhenoAge | Global follow-up in selected cases. | Repeating too early or changing treatments because of technical noise. |
Exercise: The Clock Should Not Eclipse Muscle
The DO-HEALTH exercise program was deliberately simple: 30 minutes at home, three times per week. That makes it realistic for public health. But in a longevity clinic, "doing something" is not enough. Strength, muscle mass, balance, pain, recovery and cardiorespiratory fitness should be measured.
A 72-year-old with low grip strength and difficulty standing up from a chair needs a different plan than an active adult with good muscle mass and high VO2 max. The goal is not just moving a clock. It is preventing sarcopenia, falls, fractures, loss of independence and poor resilience during illness.
This is why we combine molecular readouts with functional testing. A better clock result while the chair-stand test worsens is not good news. A modest PhenoAge improvement paired with better strength, sleep, inflammation and VO2 max is more meaningful.
Who Might Consider Omega-3, Vitamin D and Exercise as a Strategy
The reasonable profile is not "everyone". It is someone with one or more of the following: low oily-fish intake, low or unknown omega-3 index, high triglycerides, low-grade inflammation, vitamin D deficiency or insufficiency, low strength, prefrailty risk or a wish to track an intervention in an orderly way.
Some profiles need extra caution: anticoagulants or antiplatelets, upcoming surgery, history of atrial fibrillation, fish or algae allergy, kidney disease, hypercalcemia, sarcoidosis, active cancer treatment, pregnancy, polypharmacy or high-dose supplements bought online.
The dose distinction is essential. The 1 g/day used in DO-HEALTH and VITAL is not the same as 4 g/day prescription omega-3 for hypertriglyceridemia. The European Medicines Agency has warned of a dose-dependent increase in atrial fibrillation risk with omega-3 ethyl esters in patients with cardiovascular disease or risk factors, with the strongest signal at 4 g/day. That is why dose escalation should not be a DIY longevity experiment.
| Situation | Prudent decision |
|---|---|
| Eats oily fish 2-3 times per week and has normal triglycerides | Capsules may not be needed. Review the whole diet and goals. |
| No fish intake, high triglycerides or low omega-3 index | Consider EPA/DHA, dose, product quality and follow-up. |
| Low 25-OH vitamin D | Correct deficiency with monitored dosing and review the cause. |
| Low strength or prefrailty | Prioritize progressive training, enough protein and balance; supplement only if it adds value. |
| Wants to "rejuvenate" because of a commercial test | Reframe: biomarkers, function, sleep, diet, risk and safety first. |
The Progevita Approach: Measure, Intervene, Measure Again
If we use omega-3, vitamin D and exercise inside a longevity program, it is not because they are fashionable. We use a sequence:
- First, baseline map: diet, medication, history, blood pressure, ApoB, triglycerides, glucose, HbA1c, kidney function, calcium, 25-OH vitamin D, inflammation, body composition, strength and sleep.
- Second, goal: correct deficiency, improve triglycerides, reduce inflammation, rebuild strength, preserve independence or evaluate pace of aging.
- Third, simple intervention: Mediterranean pattern, oily fish or EPA/DHA when appropriate, vitamin D when indicated, progressive strength, zone 2, balance and sleep.
- Fourth, follow-up: repeat what changes decisions. An epigenetic clock does not need to be repeated every few weeks; trend over months is usually more useful.
This fits programs such as Optimization and Inflammaging: data, caution and functional goals. The aim is not chasing "4 months less" on a screen. It is building more biological reserve.
Conclusion: A Small Signal With a Bigger Lesson
DO-HEALTH does not make omega-3 an anti-aging pill. It also does not leave epigenetic clocks as lab toys. The lesson is more precise: simple interventions, maintained for years and applied to people who can benefit, can leave a trace in aging biomarkers.
The best response is not buying three supplements. It is measuring better, eating better, training better and using supplements only when they correct a real problem or support a clear goal. Months on a clock can be interesting. Years of independence, strength and low cardiometabolic burden are the prize that matters.
If you want to interpret omega-3, vitamin D, strength, inflammation and biological age inside a medical map, you can start your Progevita plan.
Frequently Asked Questions About Omega-3 and Biological Aging
Does omega-3 reduce biological age?
In DO-HEALTH, omega-3 produced small reductions in several blood epigenetic clocks over 3 years. This should not be translated into guaranteed whole-body rejuvenation or longer individual lifespan.
What dose was used in DO-HEALTH?
The trial used 1 g/day of omega-3, with 330 mg EPA and 660 mg DHA, compared with vitamin D3 2,000 IU/day and home exercise. Higher doses, such as 4 g/day, belong to different medical contexts, such as prescription treatment for hypertriglyceridemia.
Is it better to eat fish or take capsules?
For many people, oily fish 1-2 times per week within a Mediterranean-style diet is a reasonable base. Capsules may make sense when intake is low, a specific goal exists or an omega-3 index needs adjustment, with product quality, dose and safety reviewed.
Can I combine omega-3 and vitamin D without lab testing?
It may look harmless, but it is not ideal. Vitamin D accumulates and can cause problems when excessive; omega-3 can interact with anticoagulants and may raise concerns in people with atrial fibrillation. Testing and context prevent mistakes.
How often should an epigenetic clock be repeated?
It depends on the goal. For preventive follow-up, several months, often 6-12 months, usually makes more sense. Use the same sample type and laboratory where possible. Repeating too soon may measure noise rather than progress.
References
- Bischoff-Ferrari HA, Gängler S, Wieczorek M, et al. "Individual and additive effects of vitamin D, omega-3 and exercise on DNA methylation clocks of biological aging in older adults from the DO-HEALTH trial." Nature Aging. 2025;5:376-385. DOI: 10.1038/s43587-024-00793-y. PMID: 39900648.
- Bischoff-Ferrari HA, Vellas B, Rizzoli R, et al. "Effect of Vitamin D Supplementation, Omega-3 Fatty Acid Supplementation, or a Strength-Training Exercise Program on Clinical Outcomes in Older Adults: The DO-HEALTH Randomized Clinical Trial." JAMA. 2020;324(18):1855-1868. DOI: 10.1001/jama.2020.16909. PMID: 33170239.
- Bischoff-Ferrari HA, Willett WC, Manson JE, et al. "Combined Vitamin D, Omega-3 Fatty Acids, and a Simple Home Exercise Program May Reduce Cancer Risk Among Active Adults Aged 70 and Older." Frontiers in Aging. 2022;3:852643. DOI: 10.3389/fragi.2022.852643. PMID: 35821820.
- Bischoff-Ferrari HA, Gagesch M, et al. "Effects of Vitamin D, Omega-3 Fatty Acids and a Home Exercise Program on Prevention of Pre-Frailty in Older Adults: The DO-HEALTH Randomized Clinical Trial." The Journal of Nutrition, Health and Aging. 2023. PMID: 36629088.
- Rösler W, Kistler-Fischbacher M, Gängler S, et al. "Trajectories of physical function and biological aging in generally healthy older adults with and without incident invasive cancer over a three-year follow-up: findings from the DO-HEALTH study." npj Aging. 2026. DOI: 10.1038/s41514-026-00360-2.
- Belsky DW, Caspi A, Corcoran DL, et al. "DunedinPACE, a DNA methylation biomarker of the pace of aging." eLife. 2022;11:e73420. DOI: 10.7554/eLife.73420. PMID: 35029144.
- Harris WS, von Schacky C. "The Omega-3 Index: a new risk factor for death from coronary heart disease?" Preventive Medicine. 2004;39(1):212-220. DOI: 10.1016/j.ypmed.2004.02.030. PMID: 15208005.
- Zhu H, Manson JE, Cook NR, et al. "Vitamin D3 and marine omega-3 fatty acids supplementation and leukocyte telomere length: 4-year findings from the VITamin D and OmegA-3 TriaL (VITAL) randomized controlled trial." The American Journal of Clinical Nutrition. 2025;122(1):39-47. DOI: 10.1016/j.ajcnut.2025.05.003. PMID: 40409468.
- National Institutes of Health Office of Dietary Supplements. "Omega-3 Fatty Acids: Fact Sheet for Health Professionals." Updated 2024. ODS NIH.
- National Institutes of Health Office of Dietary Supplements. "Vitamin D: Fact Sheet for Health Professionals." Updated 2024. ODS NIH.
- Demay MB, Pittas AG, Bikle DD, et al. "Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline." Journal of Clinical Endocrinology & Metabolism. 2024. Endocrine Society.
- US Preventive Services Task Force. "Vitamin D Deficiency in Adults: Screening." 2021. USPSTF.
- American Heart Association. "Fish and Omega-3 Fatty Acids." Updated 2024. AHA.
- European Medicines Agency. "Omega-3-acid ethyl ester medicines: dose-dependent increased risk of atrial fibrillation." 2023. EMA.
This article is educational. If you take anticoagulants or antiplatelets, have atrial fibrillation, upcoming surgery, kidney disease, hypercalcemia, sarcoidosis, active cancer treatment, pregnancy or polypharmacy, get medical advice before starting supplements.
Related articles
Biological Aging Speed: What a 0.57x Clock Result Really Means
Biological aging speed is not a promise to live twice as long. Here is how to read DunedinPACE, GrimAge and PhenoAge with medical context.
Vive Más 2026: longevity retreat with Marcos Vázquez at Progevita
Inside Vive Más 2026: four days of science, training and health assessment with Marcos Vázquez (Fitness Revolucionario), Borja Bandera, Matías Mut and Antonio Valenzuela at our health resort in Valencia, Spain.
The Impact Project X Progevita
In a business environment shaped by speed, uncertainty, and sustained demand, companies are seeking to strengthen leadership from a more human, healthy, and strategic perspective.
A Special Retreat with Elena Devís: Science, Mindfulness and Longevity at Progēvita
A few weeks ago, we hosted a truly special retreat at Progēvita in collaboration with Elena Devís, founder of Positivamente Presente. For the 26 participants, it was far more than a medical program.